List of Excipients in Branded Drug PACLITAXEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals Inc	PACLITAXEL	paclitaxel	0480-3290	ALBUMIN HUMAN
Teva Pharmaceuticals Inc	PACLITAXEL	paclitaxel	0480-3290	SODIUM CHLORIDE
HBT Labs Inc	PACLITAXEL	paclitaxel	70534-001	ALBUMIN HUMAN
HBT Labs Inc	PACLITAXEL	paclitaxel	70534-001	HYDROCHLORIC ACID
HBT Labs Inc	PACLITAXEL	paclitaxel	70534-001	SODIUM HYDROXIDE
American Regent Inc	PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND	paclitaxel	0517-4300	ALBUMIN HUMAN
American Regent Inc	PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND	paclitaxel	0517-4300	HYDROCHLORIC ACID

Generic Drugs Containing PACLITAXEL

Company	Ingredient	NDC	Excipient
Teva Parenteral Medicines, Inc.	paclitaxel	0703-3213	ALCOHOL
Teva Parenteral Medicines, Inc.	paclitaxel	0703-3213	ANHYDROUS CITRIC ACID
Teva Parenteral Medicines, Inc.	paclitaxel	0703-3213	POLYOXYL 35 CASTOR OIL
Teva Parenteral Medicines Inc	paclitaxel	0703-4764	ALCOHOL
Teva Parenteral Medicines Inc	paclitaxel	0703-4764	ANHYDROUS CITRIC ACID
Teva Parenteral Medicines Inc	paclitaxel	0703-4764	POLYOXYL 35 CASTOR OIL
Sandoz Inc	paclitaxel	0781-3531	ALBUMIN HUMAN

What are the Most Frequently-Used Excipients in PACLITAXEL?

# Of NDCs	Excipient
3	ALBUMIN HUMAN
16	ALCOHOL
13	ANHYDROUS CITRIC ACID
4	CASTOR OIL
5	CITRIC ACID MONOHYDRATE
20	POLYOXYL 35 CASTOR OIL

Excipient Strategy and Commercial Opportunities for PACLITAXEL

Last updated: February 27, 2026

What Is the Role of Excipient Strategy in PACLITAXEL Formulations?

Excipient selection significantly impacts the stability, solubility, delivery, and shelf life of paclitaxel. Traditional formulations rely heavily on excipients to facilitate its administration and reduce toxicity. The primary goal is to optimize pharmacokinetic profiles, minimize hypersensitivity reactions, and improve patient compliance.

Key excipient components include:

• Cremophor EL (polyethoxylated castor oil): Historically used to solubilize paclitaxel but associated with hypersensitivity reactions and peripheral neurotoxicity.
• Polysorbate 80: Alternative solubilizer with similar concerns.
• Lipid-based excipients: Liposomes and nanoemulsions mitigate toxicity, enhance delivery, and improve solubility.
• Cyclodextrins: Used to increase aqueous solubility without hypersensitivity issues.

How Is Excipient Strategy Evolving for Paclitaxel?

The shift from Cremophor-based formulations to alternative strategies is driven by safety concerns and regulatory pressures. Focus areas include:

Cremophor-Free Formulations

• Albumin-bound paclitaxel (Abraxane): Approved in 2005, uses human serum albumin as a carrier, eliminating Cremophor EL and reducing hypersensitivity.
• Lipid nanoformulations: Such as Lipusu and Paclical, aim to improve solubility while avoiding toxic excipients.
• Polymer-based micelles: Use biodegradable polymers like PLGA to enhance stability and targeted delivery.

Novel Solubilization Techniques

• Use of cyclodextrins and other cyclodextrin derivatives enhances aqueous solubility.
• Polymer conjugates aim for sustained release and reduced dosing frequency.

What Commercial Opportunities Exist for New Excipient Strategies?

The market for paclitaxel formulations extends as patent exclusivity expires and biosimilar competition increases. Opportunities include:

Developing Safer, More Effective Formulations

• Reducing hypersensitivity reactions increases patient safety.
• Improving delivery to tumor tissues can enhance efficacy.

Expanding Indications

• Once toxicity barriers decrease, new indications like neoadjuvant therapy or combinations with immunotherapies become accessible.

Licensing and Collaborations

• Licensing novel excipient technologies to generic manufacturers.
• Collaborating with biotech firms developing lipid or polymer-based platforms.

Regulatory Incentives

• New formulations with improved safety profiles could qualify for orphan drug status or accelerated approval pathways.

Market Size and Growth

• The global paclitaxel market was valued at approximately USD 3.5 billion in 2021 [1].
• CAGR forecast of about 4.3% from 2022 to 2030 due to increased cancer prevalence and evolving therapeutic protocols.

Patent Landscape and Innovation Opportunities

Patent holdings focus on formulations, delivery systems, and excipient combinations. Key areas include:

• Liposomal and nanoparticle formulations targeting tumor accumulation (e.g., US patents granted for liposome-encapsulated paclitaxel).
• Polymer conjugates and micelle-based delivery platforms.
• Excipients reducing hypersensitivity and toxicity, with some patents focusing on cyclodextrin derivatives.

Patent expiration timelines suggest opportunities for both innovator companies and generics. A typical patent for paclitaxel formulations lasts until 2025-2030, after which generics can enter market with new excipient strategies.

Challenges in Excipient Development for Paclitaxel

• Regulatory approval complexity for new excipients.
• Ensuring stability and bioavailability.
• Manufacturing scalability and cost considerations.
• Meeting international safety standards (FDA, EMA, PMDA).

Conclusion

Transitioning from Cremophor-based formulations to lipid-based and cyclodextrin-enhanced systems offers substantial commercial potential. Innovation in excipient design can improve safety, efficacy, and patient compliance while opening new markets, especially in areas with high unmet needs.

Key Takeaways

• Excipient strategy for paclitaxel centers on reducing toxicity, improving delivery, and enhancing solubility.
• Lipid-based formulations and cyclodextrins are leading innovations to replace traditional excipients.
• Market opportunities exist in formulations with enhanced safety profiles and new delivery technologies.
• Patent expiration provides avenues for generics to adopt novel excipient strategies.
• Regulatory hurdles and manufacturing costs remain challenges in developing new excipients.

FAQs

1. What excipients are commonly used in traditional paclitaxel formulations?
   Cremophor EL and polysorbate 80 are standard for solubilizing paclitaxel but cause hypersensitivity risks.

2. How do albumin-bound paclitaxel formulations improve safety?
   They eliminate the need for Cremophor EL, reducing allergic reactions and neurotoxicity.

3. What are the main advantages of lipid nanoparticles in paclitaxel delivery?
   They enhance drug solubility, improve tumor targeting, and lower systemic toxicity.

4. What are the regulatory considerations for novel excipient use?
   New excipients require extensive safety and stability data, and approval timeline varies by region.

5. How might excipient innovation impact the future of paclitaxel?
   It can extend patent life, improve patient outcomes, and expand treatment indications.

---

References

[1] MarketsandMarkets. (2022). Paclitaxel market forecast. Retrieved from https://www.marketsandmarkets.com